Navigation Links
Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health

PHILADELPHIA, Oct. 1 /PRNewswire/ -- Kibow has recently completed a pilot-scale study wherein Kibow(R) Biotics were administered orally to a limited number of patients in USA, Canada, Argentina and Nigeria. The positive outcome from this study has just been published in the September issue of the peer-reviewed "Advances in Therapy" journal. This report, titled "Pilot Study of Probiotic Dietary Supplementation for Promoting Health Kidney Function in Patients with Chronic Kidney Disease," can be accessed freely at the company's website ( or the journal's website (

The company's flagship product, Kibow(R) Biotics, utilizes a patented and proprietary bowel-based enteric technology concept for use in clinical applications towards maintaining a healthy kidney function. Dr. Natarajan Ranganathan, Interim CEO and VP Research and Development, stated, "By developing an affordable, readily available and easy-to-administer dietary supplement, Kibow offers hope to all those who suffer from kidney problems in the USA and other countries worldwide in accordance with their respective governmental regulatory/registration authorities."

Kibow Biotech is also pleased to announce its successful completion of its 13th year of business today. To celebrate this milestone, Kibow is participating for the second year in the 9th annual National Kidney Foundation Kidney Walk, which will be taking place October 3rd, 2010 at the Philadelphia Zoo. In addition, Kibow would also like to take this time to announce its venture into social networking, with its first official Facebook page, "Probiotics for Kidney Health." Visitors are invited to leave comments, share their experiences, or view news links, photos, and videos. This will help interested people keep up with the latest research stories, see what's happening at Kibow Biotech, and more importantly, show their support for Kibow's progress in promoting healthy kidney function worldwide.

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow(R) Biotics," an orally consumable, enteric-coated Gel Cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

Forward-looking statements:

Kibow(R) Biotics or any other dietary supplement is not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, contact:Natarajan Ranganathan, Ph.D.Interim CEO and Senior VP (R&D)Tel: (610) 353-5130Toll Free: Website: This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
2. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
3. Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Yongye Biotechnology International Retains CCG Investor Relations
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
9. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
10. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
11. China Kangtai Cactus Biotech Announces Record Second Quarter Results
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):